依达拉奉治疗老年急性脑梗死的临床疗效被引量：21

Evaluation of edaravone injection in treatment of acute senile cerebral infarction

导出

摘要目的评价依达拉奉治疗急性老年脑梗死的临床疗效和安全性。方法将226例老年急性脑梗死患者分为依达拉奉治疗组(治疗组)115例和常规治疗组(对照组)111例,在治疗前及治疗后第7、14和21天进行欧洲卒中评分(ESS)判断治疗效果。结果共220例完成临床观察,治疗组114例,死亡1例,死于心功能衰竭;对照组106例,死亡5例,4例死于大片脑梗死、脑疝形成,1例脑干梗死者死于中枢性呼吸功能衰竭。治疗组的ESS增分率自第7天开始,治疗组第14和21天的ESS有效率分别为50．0％和62．3％,对照组分别为26．4％和34．0％,两组的差异均有统计学意义(P值均<0．01)。结论依达拉奉治疗急性老年脑梗死安全、有效。 Objective To evaluate the efficacy and safety of Edaravone on veteran patients with acute senile cerebral infarction. Methods Two hundred and twenty-six cases of acute senile cerebral infarction were randomized into Edaravone group （115 cases） and control group （111 cases）. European stroke scale （ESS） was conducted to evaluate the efficacy of both groups before the therapy and 7 d, 14 d, 21 d after initiation of the therapy. Results Two hundred and twenty cases including 114 cases of Edaravone group and 106 cases of the control group completed the clinical trial. One case of Edaravone group died of heart failure and 4 cases of the control group died of massive cerebral infarction with hernia formation and 1 died of respiratory center failure due to brain stem infarction. ESS efficacy rates of Edaravone group started to increase at 7 d after initiation of therapy and reached 50.0% and 62.3% at 14 d and 21 d whereas those of the control group were 26.4% and 34.0% respectively （P 〈 0.01）, showing statistically significant difference. Conclusion Edaravone therapy has been proven efficacious and safe in treating acute senile cerebral infarction. （Shanghai Med J, 2007, 30：91-93）

作者宁燕刘学源

机构地区同济大学附属第十人民医院神经内科

出处《上海医学》 CAS CSCD 北大核心 2007年第2期91-93,共3页 Shanghai Medical Journal

关键词依达拉奉自由基急性脑梗死老年 Edaravone Free radical Acute cerebral infarction Senile

分类号 R743.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献10

1Shichinohe H,Kuroda S,Yasuda H,et al.Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia.Brain Res,2004,1029:200-206.
2Edaravone Acute Infarction Study Group.Effect of a novel free radical scavenger,edaravone (MCI-186),on acute brain infarction.Randomized,placebo-controlled,double-blind study at multicenters.Cerebrovasc Dis,2003,15:222-229.
3Tottene A,Volsen S,Pietrobon D.alpha(1E) subunits form the pore of three cerebellar R-type calcium channels with different pharmacological and permeation properties.J Neurosci,2000,20:171-178.
4Horn J,de Haan RJ,Vermeulen M,et al.Nimodipine in animal model experiments of focal cerebral ischemia:a systematic review.Stroke,2001,32:2433-2438.
5王宇卉,邵福源,卞杰勇,强华,夏春林.半胱氨酸蛋白酶抑制剂对大鼠脑缺血模型DNA损伤的实验研究[J].中国临床康复,2003,7(7):1064-1065. 被引量：93
6Takamatsu Y,Yuki S,Watanabe T.Studies on the concentration of 3-meth1-1-1 pheny1-2-pyrazolin-5-one (MCI-186) in MCA occlusion and reperfusion model of rats.Jpn Pharmacol Ther,1997,25(suppl):S1785-S1791.
7Tanaka M.Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent.Nippon Yakurigaku Zasshi,2002,119:301-308.
8Satoh K,Ikeda Y,Shioda S,et al.Edarabone scavenges nitric oxide.Redox Rep,2002,7:219-222.
9Tabrizchi R.Edaravone Mitsubishi-Tokyo.Curr Opin Investig Drugs,2000,1:347-354.
10Takabatake Y,Uno E,Wakamatsu K,et al.The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction.No To Shinkei,2003,55:589-593.